Select Publications
Gajecki L, Lebedeva IV, Liao YR, Ambriz D, Carter LM, Kumpf M, Lovibond S, Hachey JS, Graham MS, Postow M, Lewis JS, Andrew DP, Baca M, Schöder H, Larson SM, Veach DR, Krebs S. IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies. J Nucl Med. 2025 Apr 1;66(4):605-611. PMID: 39978817.
Kurtz K*, Eibler L*, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Kesner AL, Cheung NKV, Schöder H, Gajecki L, Cheal SM, Larson SM+, Scheinberg DA+, Krebs S+. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics 2023 Oct 8;13(15):5469-5482. PMID: 37908719.
*Contributed equally as first authors; +Contributed equally as senior authors
Dacek MM, Veach DR, Cheal SM, Carter LM, McDevitt MR, Punzalan B, Burnes Vargas D, Kubik TZ, Monette S, Santich BH, Yang G, Ouerfelli O, Kesner AL, Cheung NV, Scheinberg DA+, Larson SM+ and Krebs S+. Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjug Chem. 2021 Apr 21;32(4):649-654. PMID:33819023.
+Contributed equally as senior authors
Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico P, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS. First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography. J Nucl Med. 2020 Nov;61(11):1580-1587. PMID: 32169913.
Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O’Donoghue JA. Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685. PMID:30374529.